Athera and Medirista Sign Agreement
News Aug 27, 2013
Athera Biotechnologies AB has announced that the rights to the recombinant Annexin A5 have been transferred to Medirista AB.
Medirista is a biotech company owned by the original innovators of the Annexin A5 project, Johan and Anna Frostegård.
The whole patent portfolio together with key preclinical assets have been transferred. Athera will continue its focus on development of the lead product candidate, the fully human antibody in atherosclerosis.
Recombinant Annexin A5 has been developed to preclinical stage by Athera as an anti-inflammatory therapy, primarily targeting prevention of complications following vascular surgery.
Annexin A5 has been shown to beneficially affect remodelling in a preclinical model of coronary bypass grafting. Another study showed that low doses of Annexin A5 could prevent injury in a model mimicking catheter-based percutaneous interventions (PCI) in mice.
Millions of PCI procedures are done per year due to acute coronary syndrome (ACS) and the number is rapidly increasing.
Computational Model Underlines Need for Personalised Approach to SepsisNews
A computational model of the human immune system has enabled researchers to explore the challenges of tackling sepsis.READ MORE
Allergies and Asthma Possibly Linked to Female HormonesNews
Fluctuations in female sex hormones could play a role in the development of allergies and asthma, a major review of evidence suggests. Analysis of studies involving more than 500,000 women highlights a link between asthma symptoms and key life changes such as puberty and menopause. Further investigation could help explain why asthma is more common in boys than girls in childhood, but more common in teenage girls and women following puberty.READ MORE
Comments | 0 ADD COMMENT
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018